Estados Unidos · Bolsa y Finanzas · The Motley Fool

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

Publicado por The Motley Fool · Estados Unidos hace 8 h

BioNTech announced that it was stopping a Phase 2 clinical trial for autogene cevumeran, which it was testing as an adjuvant treatment for certain patients with colorectal cancer.…

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

También te puede interesar

Bessent warns Zelenskyy to 'be very careful' about claims U.S. is throttling Starlink

What Is Starshield, SpaceX’s Military-Grade Satellite Internet Service Ukraine Relies On?

Everyone’s watching the Elizabeth Holmes documentary ‘You Can See Everything’

The Nuclear Power Shortcut That Could Add Gigawatts to the U.S. Grid

Anthropic commits billions to a 'public benefit fund'

‘Street Fighter’ hits $31M in box office debut as moviegoing jumps 48%

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

Compartir

También te puede interesar

Bessent warns Zelenskyy to 'be very careful' about claims U.S. is throttling Starlink

What Is Starshield, SpaceX’s Military-Grade Satellite Internet Service Ukraine Relies On?

Everyone’s watching the Elizabeth Holmes documentary ‘You Can See Everything’

The Nuclear Power Shortcut That Could Add Gigawatts to the U.S. Grid

Anthropic commits billions to a 'public benefit fund'

‘Street Fighter’ hits $31M in box office debut as moviegoing jumps 48%